WallStSmart
CRNX

Crinetics Pharmaceuticals Inc

NASDAQ: CRNX · HEALTHCARE · BIOTECHNOLOGY

$38.44
+0.76% today

Updated 2026-04-29

Market cap
$3.99B
P/E ratio
P/S ratio
519.04x
EPS (TTM)
$-4.95
Dividend yield
52W range
$26 – $58
Volume
1.1M

WallStSmart proprietary scores

34
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+
7.8
Quality
B+
2.5
Profitability
F
6.7
Valuation
B
4/9
Piotroski F-Score
Moderate
6.4
Altman Z-Score
Safe zone
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$83.50
+117.22%
12-Month target
Intrinsic (DCF)
$74.34
Margin of safety
+35.96%
3 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Altman Z 6.35 — safe zone
+ Revenue growth 158.40% QoQ
+ 35.96% below intrinsic value
Risks
- Thin margins at 0.00%
- Negative free cash flow $-93.36M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$4.74M$4.01M$1.04M$7.70M$7.70M
Net income$-159.95M$-214.53M$-298.41M$-465.32M$-122.81M
EPS$-4.95
Free cash flow$-116.86M$-171.00M$-229.81M$-383.68M$-93.36M
Profit margin-3,376.69%-5,345.85%-28,720.69%-6,046.22%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
CRNX$3.99B347.32.56.77.8+35.96%Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Crinetics Pharmaceuticals Inc trades at $38.44. Our Smart Value Score of 34/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 6.35, it sits in the safe zone. TTM revenue stands at $7.70M. Our DCF model estimates intrinsic value at $74.34.

Frequently asked questions

What is Crinetics Pharmaceuticals Inc's stock price?
Crinetics Pharmaceuticals Inc (CRNX) trades at $38.44.
Is Crinetics Pharmaceuticals Inc overvalued?
Smart Value Score 34/100 (Grade F, Strong Sell). DCF value $74.34.
What is the price target of Crinetics Pharmaceuticals Inc (CRNX)?
The analyst target price is $83.50, representing +117.2% upside from the current price of $38.44.
What is the intrinsic value of Crinetics Pharmaceuticals Inc (CRNX)?
Based on our DCF model, intrinsic value is $74.34, a +36.0% margin of safety versus $38.44.
What is Crinetics Pharmaceuticals Inc's revenue?
TTM revenue is $7.70M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
6.35 — safe zone.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio519.04x
ROE-40.20%
Beta0.31
50D MA$38.85
200D MA$40.58
Shares out0.10B
Float0.10B
Short ratio
Avg volume1.1M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years